What's new

Human medicines European public assessment report (EPAR): Imjudo, tremelimumab, Date of authorisation: 20/02/2023, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Imjudo, tremelimumab, Date of authorisation: 20/02/2023, Revision: 8, Status: Authorised

Feb 18, 2025 - 16:18
 0
Human medicines European public assessment report (EPAR): Imjudo, tremelimumab, Date of authorisation: 20/02/2023, Revision: 8, Status: Authorised
Human medicines European public assessment report (EPAR): Imjudo, tremelimumab, Date of authorisation: 20/02/2023, Revision: 8, Status: Authorised
Read More

Tags:

Previous Article

STAT+: FDA’s head of device safety among employees terminated in ‘challenging’ w...

Next Article

Alabama hospital to adopt outpatient-only model through health system partnership

Related Posts

Pharmacovigilance Risk Assessment Committee (PRAC): 10 - 13 February 2025, European Medicines Agency, Amsterdam, the Netherlands, from 10 February 2025 to 13 February 2025

Pharmacovigilance Risk Assessment Committee (PRAC): 10 ...

Feb 10, 2025  0

EMEA-003490-PIP01-23

EMEA-003490-PIP01-23

Feb 13, 2025  0

PSUSA/00000408/202405

PSUSA/00000408/202405

Feb 9, 2025  0